You can buy or sell AVROBIO and other stocks, options, and ETFs commission-free!
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA. The listed name for AVRO is AVROBIO, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 15, Pre-Market